TLR9 and B-cell chronic lymphocytic leukemia: In this regard, BTK-unmutated CLL cells, whose BCR signaling is still inhibited by ibrutinib, may try to compensate the decrease of pro-survival signals no longer gained through the BCR pathway by activating other pathways, including MYC and/or TLR9 [69–73].